Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$217.81 USD

217.81
770,893

-0.25 (-0.11%)

Updated May 24, 2024 04:00 PM ET

After-Market: $217.88 +0.07 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why Is Biogen (BIIB) Up 7.7% Since Last Earnings Report?

by Zacks Equity Research

Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

The Zacks Analyst Blog Highlights Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics

by Zacks Equity Research

Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics are part of the Zacks top Analyst Blog.

Biotech Stock Roundup: BIIB's Acquisition, PTCT, LRMR Gain on Updates & More News

by Zacks Equity Research

Biogen (BIIB) and PTC Therapeutics, Inc. (PTCT) are in the spotlight following acquisition news and regulatory updates, respectively.

Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline

by Zacks Equity Research

Biogen's (BIIB) acquisition of private biotech, HI-Bio, is set to expand its rare disease pipeline by adding the latter's lead asset, felzartamab.

Larimar (LRMR) Up on Lifting of Partial Clinical Hold on FA Study

by Zacks Equity Research

The FDA removes the partial clinical hold on Larimar's (LRMR) nomlabofusp clinical program for the treatment of patients with Friedreich's Ataxia.

Why Biogen Inc. (BIIB) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Ionis (IONS), Biogen Down on Ending Development of ALS Drug

by Zacks Equity Research

Ionis (IONS) and Biogen (BIIB) stop developing their experimental ALS drug after a phase I/II study failed to show improvement in patients.

Biogen (BIIB) Partner Begins Filing for Leqembi SC Autoinjector

by Zacks Equity Research

Biogen (BIIB) and Eisai start the rolling submission of a biologics license application to the FDA for Leqembi subcutaneous autoinjector as a weekly maintenance dosing regimen for early Alzheimer's disease.

Ionis (IONS) Q1 Loss Narrower Than Expected, Sales Miss

by Zacks Equity Research

Ionis (IONS) posts mixed first-quarter 2024 results. The company continues to focus on pipeline development.

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Denali (DNLI) Q1 Earnings Miss, Pipeline Progress in Focus

by Zacks Equity Research

Denali (DNLI) Q1 loss narrows year over year due to lower expenses despite nil revenues.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates

by Zacks Equity Research

Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.

The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals

by Zacks Equity Research

Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.

Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX

by Zacks Equity Research

Biogen (BIIB) and Bristol Myers (BMY) are in focus following Q1 earnings announcement.

Stock Market News for Apr 25, 2024

by Zacks Equity Research

U.S. stocks ended mixed on Wednesday in choppy trading as interest rate fears and a rise in Treasury yields weighed on the enthusiasm surrounding earnings from a spate of big companies.

Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake

by Zacks Equity Research

Biogen's (BIIB) first-quarter earnings beat estimates but sales miss the mark. While sales of key drugs like Tecfidera, Tysabri & Spinraza declined, the company's cost-saving efforts show promise.

Biogen (BIIB) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

What's in Store for Biogen (BIIB) This Earnings Season?

by Zacks Equity Research

Biogen's (BIIB) sales in the first quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have been moderate.

Gear Up for Biogen (BIIB) Q1 Earnings: Wall Street Estimates for Key Metrics

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for Biogen (BIIB), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.

Sage (SAGE) Down 20% on Parkinson's Study Missing Primary Goal

by Zacks Equity Research

Data from a mid-stage study show that Sage's (SAGE) experimental oral drug failed to show a statistically significant difference in treating patients with Parkinson's disease compared with a placebo.

Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biogen Inc. (BIIB) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biogen Inc. (BIIB) Falls More Steeply Than Broader Market: What Investors Need to Know

by Zacks Equity Research

In the closing of the recent trading day, Biogen Inc. (BIIB) stood at $214.83, denoting a -0.37% change from the preceding trading day.